NCT04421742View on ClinicalTrials.gov

The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

February 8, 2019

Study Completion Date

May 23, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Beclomethasone Dipropionate/Formoterol Fumarate

BDP/FF NEXThaler® 100/6 μg b.i.d.

Trial Locations (1)

43125

Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Italy, Parma

All Listed Sponsors
collaborator

University of Parma

OTHER

lead

Alfredo Antonio Chetta

OTHER

NCT04421742 - The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients. | Biotech Hunter | Biotech Hunter